Insulet (PODD Quick QuotePODD - Free Report) reported $488.5 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 23.2%. EPS of $0.55 for the same period compares to $0.38 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $463.13 million, representing a surprise of +5.48%. The company delivered an EPS surprise of -3.51%, with the consensus EPS estimate being $0.57.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- International Omnipod

  : $128.10 million versus $116.35 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +23.5% change.

• Revenue- U.S. Omnipod

  : $352.30 million versus the six-analyst average estimate of $339.05 million. The reported number represents a year-over-year change of +27.3%.

• Revenue- Total Omnipod

  : $480.40 million versus $455.38 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +26.3% change.

• Revenue- Drug Delivery

  : $8.10 million compared to the $4.36 million average estimate based on six analysts. The reported number represents a change of -49.4% year over year.

View all Key Company Metrics for Insulet here>>>

Shares of Insulet have returned -3.7% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.